Fig. 2.
Of the 254 patients enrolled and consented for study qualification, 83 discontinued before device implantation and randomization, and 1 mistakenly received open-label drug (intrathecal gabapentin). The remaining 170 patients underwent device implantation and study drug or placebo therapy.